Evidence map›Paper›PMID 33507449›Full record

ArticleAnnals of surgical oncology2021

Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis.

Boateng Kubi, Richard Nudotor, Nadege Fackche, Wasay Nizam, Jordan M Cloyd, Travis E Grotz, Keith F Fournier, Sean P Dineen, Benjamin D Powers, Jula Veerapong and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 1 country.

Boateng KubiDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Richard NudotorDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Nadege FackcheDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Wasay NizamDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Jordan M CloydDivision of Surgical Oncology, Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Travis E GrotzDivision of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, USA.
Keith F FournierDepartment of Surgical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sean P DineenDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Department of Oncologic Sciences, Morsani College of Medicine, Tampa, FL, USA.
Benjamin D PowersDepartment of Gastrointestinal Oncology, Moffitt Cancer Center, Department of Oncologic Sciences, Morsani College of Medicine, Tampa, FL, USA.
Jula VeerapongDivision of Surgical Oncology, Department of Surgery, University of California, San Diego, CA, USA.
Joel M BaumgartnerDivision of Surgical Oncology, Department of Surgery, University of California, San Diego, CA, USA.
Callisia N ClarkeDivision of Surgical Oncology, Department of Surgery, Medical College of Wisconsin, Milwaukee, WI, USA.
Sameer H PatelDepartment of Surgery, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Laura A LambertDivision of Surgical Oncology, Department of Surgery, University of Massachusetts Medical School, Worcester, MA, USA.
Daniel E AbbottDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI, USA.
Kara A Vande WalleDivision of Surgical Oncology, Department of Surgery, University of Wisconsin, Madison, WI, USA.
Mustafa RaoofDivision of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Byrne LeeDivision of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, CA, USA.
Shishir K MaithelDivision of Surgical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Charles A StaleyDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Fabian M JohnstonDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA.
Jonathan B GreerDepartment of Surgery, Johns Hopkins University, Baltimore, MD, USA. jgreer13@jhmi.edu.
Johns Hopkins University · USCity Of Hope National Medical Center · USMoffitt Cancer Center · USUniversity of California, San Diego · USUniversity of Wisconsin–Madison · USEmory University · USMayo Clinic in Arizona · USMedical College of Wisconsin · USThe Ohio State University Wexner Medical Center · USThe University of Texas MD Anderson Cancer Center · USUniversity of Cincinnati Medical Center · USUniversity of Massachusetts Chan Medical School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a major operation frequently necessitating red blood cell transfusion. Using multi-institutional data from the U.S. HIPEC Collaborative, this study sought to determine the association of perioperative allogenic blood transfusion (PABT) with perioperative outcomes after CRS/HIPEC.

methodsThis retrospective cohort study analyzed patients who underwent CRS/HIPEC for peritoneal surface malignancy between 2000 and 2017. Propensity score-matching was performed to mitigate bias. Univariate analysis was used to compare demographic, preoperative, intraoperative, and postoperative variables. Factors independently associated with PABT were identified using multivariate analysis.

resultsThe inclusion criteria were met by 1717 patients, 510 (29.7%) of whom required PABT. The mean Peritoneal Cancer Index (PCI) of our cohort was 14.8 ± 9.3. Propensity score-matching showed an independent association between PABT and postoperative risk of pleural effusion, hemorrhage, pulmonary embolism, enteric fistula formation, Clavien-Dindo grades 3 and 4 morbidity, longer hospital stay, and reoperation (all P < 0.05 in the multivariate analysis). Compared with the patients who received 1 to 5 red blood cell (RBC) units, the patients who received more than 5 units had a greater risk of renal impairment, a longer intensive care unit (ICU) stay, and more postoperative infections. Finally, PABT was an independent predictor of worse survival for patients with appendiceal and colorectal primaries.

conclusionEven low levels of PABT for patients undergoing CRS/HIPEC are independently associated with a greater risk of infectious and non-infectious postoperative complications, and this risk is increased for patients receiving more than 5 RBC units. Worse survival was independently predicted by PABT for patients with peritoneal carcinomatosis of an appendiceal or colorectal origin.

Indexed as

Appendiceal NeoplasmsHyperthermia, InducedPeritoneal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsBlood TransfusionChemotherapy, Cancer, Regional PerfusionCombined Modality TherapyCytoreduction Surgical ProceduresHumansRetrospective StudiesSurvival Rate

Identifiers

PMID33507449
OpenAlexW3125007074

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.